LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Pregnancy Outcomes in Women With SARS-CoV-2 Infection During the First and Second Waves of the COVID-19 Pandemic in a Tertiary Care Hospital in Ayodhya, Uttar Pradesh, India: A Comparative Study.

    Ambedkar, Diksha / Yadav, Yogesh / Dubey, Pawan / Kumar, Vijay / Sharma, Rina / Mishra, Charu

    Cureus

    2023  Volume 15, Issue 2, Page(s) e34969

    Abstract: Introduction Pregnancy is an altered immunological state and not necessarily an immune-compromised state. These immune changes subject pregnant women to increased susceptibility to infection. During the coronavirus disease 2019 (COVID-19) pandemic, ... ...

    Abstract Introduction Pregnancy is an altered immunological state and not necessarily an immune-compromised state. These immune changes subject pregnant women to increased susceptibility to infection. During the coronavirus disease 2019 (COVID-19) pandemic, pregnant women were more susceptible to serious illness for reasons other than their immune response. The purpose of this study was to compare the feto-maternal outcome (morbidity and mortality) in relation to pre-existing maternal co-morbidities, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-related disease severity, and its impact on the mode of delivery and long-term sequelae in pregnant women in the first and second waves of the COVID-19 pandemic. Materials and methods This was a hospital-based comparative study carried out on 101 pregnant patients during the first wave (April 2020 to December 2020) and 22 patients in the second wave (March 2021 to July 2021) of the COVID-19 pandemic, in Rajashri Dashrath Autonomous State Medical College, Ayodhya, India. All pregnant women with COVID-19 in the first and second waves were included. Non-pregnant patients with COVID-19 infection, pregnant patients lost to follow-up, pregnant patients without COVID-19 infection, and patients in the puerperal period were excluded. Results Seventy-three (72.27%) patients in the first wave and 12 (54.54%) in the second wave were asymptomatic. Those with mild disease numbered 20 (25.74%) in the first wave and six (27.27%) in the second wave. Disease severity was more in the second wave, that is four (18.18%) as compared to one (0.99%) in the first wave. Severe anemia was the most common co-morbidity associated with both first (n=4, 3.96%) and second (n=5, 22.72%) waves. Four (6.45%) spontaneous abortions occurred in the first wave as compared to three (20%) in the second wave. Intensive care unit (ICU) admission was more in the second wave (n=4, 26.66%) as compared to the first wave (n=1, 1.61%). Two (13.33%) maternal deaths occurred in the second wave and none in the first wave. Cesarean sections in both the first and second waves were performed for obstetric indications only. No newborns tested positive in the COVID-19 reverse transcription-polymerase chain reaction (RT-PCR) in the first and second waves at the time of birth; however, three (4.83%) tested positive on day five of birth in the first wave. Fever was the most common presentation in newborns; seven (11.26%) in the first wave and three (20%) in the second wave. No neonatal death occurred in the first or second waves. No congenital anomalies were noted in the first or second waves of COVID-19. Conclusion In this study, we found that the maximum number of COVID-19-positive pregnant patients in both the first and second waves of COVID-19 were either asymptomatic or had mild infections. Second-wave infection was more lethal as compared to the first wave in terms of adverse maternal as well as fetal outcomes. No gestational age was an exception to the severity of disease and its adverse feto-maternal outcome. In our study, maternal co-morbidities did not impact the overall outcome. All cesarean sections were performed for indications other than COVID-19 infection. Long-term sequelae associated with COVID-19 were seen in both groups but more so in the second wave. No long-term sequelae like congenital anomalies in the babies were associated with COVID-19 either in the first or second wave.
    Language English
    Publishing date 2023-02-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.34969
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Current Perspectives on Biological Therapy for COPD.

    Yadav, Ambedkar Kumar / Gu, Wenhua / Zhang, Tongyangzi / Xu, Xianghuai / Yu, Li

    COPD

    2023  Volume 20, Issue 1, Page(s) 197–209

    Abstract: Chronic obstructive pulmonary disease (COPD) is a chronic, complex, and heterogeneous condition with significant mortality, morbidity, and socioeconomic burden. Given the heterogeneity, the current management of COPD, which mainly relies on ... ...

    Abstract Chronic obstructive pulmonary disease (COPD) is a chronic, complex, and heterogeneous condition with significant mortality, morbidity, and socioeconomic burden. Given the heterogeneity, the current management of COPD, which mainly relies on bronchodilators and corticosteroids, cannot consider all COPD populations. Moreover, the present treatment modalities are directed at minimizing symptoms and reducing the risk of a future attack, but they exhibit few meaningful anti-inflammatory activities in preventing and reducing disease progression. Therefore, new anti-inflammatory molecules are needed to manage COPD better. Use of targeted biotherapy may obtain better results by increasing understanding of the underlying inflammatory process and identifying new biomarkers. In this review, we focus briefly on study of the underlying inflammatory process in the pathogenesis of COPD for better identification of novel target biomarkers, and we describe a novel class of anti-inflammatory biologics that are already under evaluation for their use in managing COPD.
    MeSH term(s) Humans ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Anti-Inflammatory Agents/therapeutic use ; Adrenal Cortex Hormones/therapeutic use ; Biomarkers ; Biological Therapy
    Chemical Substances Anti-Inflammatory Agents ; Adrenal Cortex Hormones ; Biomarkers
    Language English
    Publishing date 2023-06-29
    Publishing country England
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2171107-0
    ISSN 1541-2563 ; 1541-2555
    ISSN (online) 1541-2563
    ISSN 1541-2555
    DOI 10.1080/15412555.2023.2187210
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Antiviral treatment in COVID-19: which is the most promising?-a narrative review.

    Yadav, Ambedkar Kumar / Wen, Siwan / Xu, Xianghuai / Yu, Li

    Annals of palliative medicine

    2021  Volume 10, Issue 1, Page(s) 707–720

    Abstract: The whole world is battling through coronavirus disease 2019 (COVID-19) which is a fatal pandemic. In the early 2020, the World Health Organization (WHO) declared it as a global health emergency without definitive treatments and preventive approaches. In ...

    Abstract The whole world is battling through coronavirus disease 2019 (COVID-19) which is a fatal pandemic. In the early 2020, the World Health Organization (WHO) declared it as a global health emergency without definitive treatments and preventive approaches. In the absence of definitive therapeutic agents, this thorough review summarizes and outlines the potency and safety of all molecules and therapeutics which may have potential antiviral effects. A number of molecules and therapeutics licensed or being tested for some other conditions were found effective in different in vitro studies as well as in many small sample-sized clinical trials and independent case studies. However, in those clinical trials, there were some limitations which need to be overcome to find the most promising antiviral against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In conclusion, many of above-mentioned antivirals seems to have some therapeutic effects but none of them have been shown to have a strong evidence for their proper recommendation and approval in the treatment of COVID-19. Constantly evolving new evidences, exclusive adult data, language barrier, and type of study (observational, retrospective, small-sized clinical trials, or independent case series) resulted to the several limitations of this review. The need for multicentered, large sample-sized, randomized, placebo-controlled trials on COVID-19 patients to reach a proper conclusion on the most promising antiviral agent is warranted.
    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/pharmacology ; Adenosine Monophosphate/therapeutic use ; Alanine/analogs & derivatives ; Alanine/pharmacology ; Alanine/therapeutic use ; Amides/pharmacology ; Amides/therapeutic use ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antiviral Agents/therapeutic use ; Azetidines/pharmacology ; Azetidines/therapeutic use ; COVID-19/therapy ; Chloroquine/pharmacology ; Chloroquine/therapeutic use ; Drug Combinations ; Humans ; Hydroxychloroquine/pharmacology ; Hydroxychloroquine/therapeutic use ; Immunization, Passive ; Indoles/pharmacology ; Indoles/therapeutic use ; Interferons/pharmacology ; Interferons/therapeutic use ; Ivermectin/pharmacology ; Ivermectin/therapeutic use ; Lopinavir/pharmacology ; Lopinavir/therapeutic use ; Oseltamivir/pharmacology ; Oseltamivir/therapeutic use ; Purines/pharmacology ; Purines/therapeutic use ; Pyrazines/pharmacology ; Pyrazines/therapeutic use ; Pyrazoles/pharmacology ; Pyrazoles/therapeutic use ; Ribavirin/pharmacology ; Ribavirin/therapeutic use ; Ritonavir/pharmacology ; Ritonavir/therapeutic use ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use ; Thiazoles/pharmacology ; Thiazoles/therapeutic use
    Chemical Substances Amides ; Antibodies, Monoclonal, Humanized ; Antiviral Agents ; Azetidines ; Drug Combinations ; Indoles ; Purines ; Pyrazines ; Pyrazoles ; Sulfonamides ; Thiazoles ; lopinavir-ritonavir drug combination ; Oseltamivir (20O93L6F9H) ; Lopinavir (2494G1JF75) ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Ribavirin (49717AWG6K) ; Hydroxychloroquine (4QWG6N8QKH) ; Ivermectin (70288-86-7) ; Chloroquine (886U3H6UFF) ; Interferons (9008-11-1) ; umifenovir (93M09WW4RU) ; favipiravir (EW5GL2X7E0) ; tocilizumab (I031V2H011) ; baricitinib (ISP4442I3Y) ; Ritonavir (O3J8G9O825) ; Alanine (OF5P57N2ZX) ; nitazoxanide (SOA12P041N)
    Language English
    Publishing date 2021-01-11
    Publishing country China
    Document type Journal Article ; Review
    ZDB-ID 2828544-X
    ISSN 2224-5839 ; 2224-5839
    ISSN (online) 2224-5839
    ISSN 2224-5839
    DOI 10.21037/apm-20-1755
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Utility of Acute Normovolemic Hemodilution in Major Surgeries in Rural Area: A Prospective Comparative Study from North India.

    Rai, Sujeet / Verma, Satyajeet / Yadav, Pramod Kumar / Ahmad, Jawed / Yadav, Harikesh Kumar

    Anesthesia, essays and researches

    2017  Volume 11, Issue 4, Page(s) 909–912

    Abstract: ... at MRA Medical College Ambedkar Nagar, Uttar Pradesh, India. during from September 2015 to September 2016 ...

    Abstract Introduction: Easy availability of autologous blood is difficult in rural areas. Acute normovolemic hemodilution (ANH) has been found to be an effective alternative in major surgeries where we are expecting major blood loss.
    Patients and methods: A prospective comparative study was designed to evaluate the utility of ANH patients (patients receiving autologous blood) during major operations done at MRA Medical College Ambedkar Nagar, Uttar Pradesh, India. during from September 2015 to September 2016. A total of 60 patients undergoing major surgeries were randomly assigned into two groups of thirty patients' each. Group I received homologous blood intraoperative only when required. In Group II ANH was initiated to a target hematocrit of 30% after induction of anesthesia. Various parameters such as demographic, biochemical, and hemodynamic were compared.
    Results: The mean value of blood withdrawn in ANH group was 650.5 ± 228 ml and it was replaced with an equal volume of 6% hydroethyl starch. There was no statistically significant variation in mean hemocrits levels in both the groups at various stages of the study. Hematocrits decreased significantly in both the groups at various stages as compared to preoperative values. The heart rate and mean blood pressure were almost similar and without statistically significant differences in both groups. Surgical blood loss in Group I was 895.29 ± 568.30 ml as compared to 765 ± 506 ml in Group II. The difference was statistically insignificant (
    Conclusion: It concludes that ANH up to a target hematocrit of 30% is safe and effective in reducing the need for homologous blood in various major surgeries in institutes in rural areas.
    Language English
    Publishing date 2017-11-15
    Publishing country India
    Document type Journal Article
    ZDB-ID 2626233-2
    ISSN 2229-7685 ; 0259-1162
    ISSN (online) 2229-7685
    ISSN 0259-1162
    DOI 10.4103/aer.AER_86_17
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top